SCHEMBL5050767

SCHEMBL5050767

CC1(C)CCC(C)(C)c2c(NCc3ccc(F)cc3)cc(C(O)/C=C/c3ccc(C(=O)O)cc3)cc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 11/20 0.57
RARG P13631 11/20 0.57
RARA P10276 8/20 0.57
RXRA P19793 9/20 0.41
HNF4A P41235 1/20 0.41
CYP26A1 O43174 3/20 0.39
CYP3A4 P08684 3/20 0.39
RXRB P28702 2/20 0.38
RXRG P48443 1/20 0.38
CYP26B1 Q9NR63 1/20 0.38
PPARA Q07869 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
GMNN O75496 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5050770 1.00 RARB (0.57) RARBRARGRARARXRAHNF4A
SCHEMBL5050774 1.00 RARB (0.57) RARBRARGRARARXRAHNF4A
SCHEMBL5048384 0.92 RARB (0.58) RARBRARGRARARXRAHNF4A
SCHEMBL5048381 0.92 RARB (0.58) RARBRARGRARARXRAHNF4A
SCHEMBL5048380 0.92 RARB (0.58) RARBRARGRARARXRAHNF4A
SCHEMBL5047113 0.92 RARB (0.55) RARBRARGRARARXRAHNF4A
SCHEMBL5047004 0.90 RARB (0.55) RARBRARGRARARXRACYP26A1
SCHEMBL5046994 0.90 RARB (0.55) RARBRARGRARARXRACYP26A1
SCHEMBL5046999 0.90 RARB (0.55) RARBRARGRARARXRACYP26A1
SCHEMBL5044015 0.88 RARA (0.43) RARBRARGRARARXRAHNF4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed
EP-1513803-A1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS Galderma Research & Development, S.N.C. (FR) 2005-03-16 EP disclosed
WO-2003101945-A1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARB 2/4885RARG 3/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.